Clinical Trials Logo

Clinical Trial Summary

This trial is a single-site, randomised, double blind, placebo-controlled, two-armed parallel-group trial in healthy adult volunteers. The trial will investigate the effect of oral supplementation of a probiotic strain on the ability to attenuate exercise-induced deterioration of intestinal barrier function and gastrointestinal symptoms.


Clinical Trial Description

The trial includes a run-in period of two weeks duration followed by a six weeks intervention period.

After having given their written informed consent, subjects will complete screening procedures to evaluate their eligibility for the trial and complete a run-in period of minimum two weeks duration to washout possible pre-trial probiotics. At the screening visit (visit 1), subjects will also perform a VO2max test on a running treadmill to determine their individual VO2max.

After baseline assessments at visit 2 and 3, the subjects will be randomly assigned to one of the two treatment groups (active or placebo product) in a ratio of 1:1. The two arms will be stratified for gender.

The subjects will consume 1-2 capsules once daily, together with breakfast, for six weeks starting at Day 1, the day after Visit 3. During the entire run-in and intervention period the subjects will be asked not to consume any other probiotic products. During the entire trial subjects should maintain their habitual life style in relation to physical activity level, diet and sleep habits.

At Visit 2, 3, 4 and 5, the small intestinal permeability will be evaluated by the L:R ratio measured in urine obtained 5 hours after oral ingestion of a lactulose and rhamnose solution. The permeability test will be performed in combination with a 1 hour treadmill running challenge when performed at Visit 3 and Visit 5. The treadmill run will be performed at a velocity corresponding to 80% of the subjects individually measured VO2max.

Faecal, urine and blood samples will be collected at Visit 2, 3, 4 and 5 for evaluation of the secondary objectives. The faecal samples collected will be: First bowel movement post-permeability test at Visit 2, first bowel movement post-exercise test at Visit 3, first bowel movement post-permeability test at Visit 4 and the first bowel movement post-exercise at Visit 5. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03027583
Study type Interventional
Source Chr Hansen
Contact
Status Completed
Phase N/A
Start date March 1, 2017
Completion date September 15, 2017

See also
  Status Clinical Trial Phase
Completed NCT03957239 - The Effect of a Cranberry Beverage on Intestinal Permeability and Gastrointestinal Function in Generally Healthy Adults N/A
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Recruiting NCT04109352 - Labelled Carbon Sucrose Breath Test (13C-SBT) as a Marker of Environmental Enteropathy
Completed NCT01424306 - Diet and Systemic Inflammation N/A
Completed NCT01241201 - Intestinal Barrier Function and Probiotics. N/A
Completed NCT01477034 - Vitamin D and Adipose Tissue Inflammation N/A
Recruiting NCT05257200 - Gut Permeability and Bariatric-metabolic Surgery
Completed NCT03704727 - The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in Chemotherapy N/A
Completed NCT01049386 - Intestinal Permeability Phase 2
Recruiting NCT04979130 - Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) Phase 4
Recruiting NCT06262880 - Dietary Supplementation on Gastrointestinal Barrier Function N/A
Completed NCT01756040 - Intestinal Permeability in Preterm Infants Phase 1
Active, not recruiting NCT04083950 - Induction of Gut Permeability by an Oral Vaccine Early Phase 1
Completed NCT03113240 - Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients Phase 3